Abstract | OBJECTIVE: The aim of the present study was to analyze treatment outcomes and identify videourodynamic factors predictive of successful urethral onabotulinumtoxinA treatment of neurogenic and non-neurogenic detrusor underactivity (DU). METHODS: Patients with DU refractory to medical treatment were treated with injections totaling 100 U onabotulinumtoxinA into the urethral sphincter. Treatment outcomes were assessed 1 month after treatment using the Global Response Assessment. The videourodynamic parameters evaluated included bladder neck status during voiding, bladder sensation, detrusor pressure, maximum flow rate, and post-void residual volume. Treatment outcome was analyzed by patient and baseline videourodynamic characteristics. RESULTS: In all, 60 patients (27 with non-neurogenic and 33 with neurogenic DU) were included in the study and received urethral sphincter injections of 100 U onabotulinumtoxinA in total. Good outcomes were reported in 36 (60%) patients (20 [74.1%] with non-neurogenic and 16 [48.5%] with neurogenic DU). Treatment outcome was significantly better in patients with non-neurogenic than neurogenic DU (P = .039). However, good treatment outcome was not related to age, gender, or any videourodynamic variables, except for an open bladder neck during voiding vs non-opening bladder neck (94.3% vs. 12.0%; P < .0001). The duration of the therapeutic effect was similar between patients with non-neurogenic and neurogenic DU (mean [± SD] 7.37 ± 3.69 vs. 7.69 ± 3.18 months, respectively; P = .788). In all, 12 patients reported de novo urinary incontinence after urethral onabotulinumtoxinA injection, 4 of whom developed stress urinary incontinence and 8 who had exacerbated urgency urinary incontinence. CONCLUSION: Urethral sphincter injection of onabotulinumtoxinA is effective in 60% of patients with DU. Careful videourodynamic interpretation of bladder neck opening enables urologists to select appropriate candidates for onabotulinumtoxinA treatment.
|
Authors | Yuan-Hong Jiang, Jia-Fong Jhang, Sheng-Fu Chen, Hann-Chorng Kuo |
Journal | Lower urinary tract symptoms
(Low Urin Tract Symptoms)
Vol. 11
Issue 1
Pg. 66-71
(Jan 2019)
ISSN: 1757-5672 [Electronic] Australia |
PMID | 29024564
(Publication Type: Journal Article)
|
Copyright | © 2017 John Wiley & Sons Australia, Ltd. |
Chemical References |
- Urological Agents
- Botulinum Toxins, Type A
|
Topics |
- Aged
- Botulinum Toxins, Type A
(administration & dosage)
- Female
- Humans
- Injections
- Male
- Middle Aged
- Off-Label Use
- Retrospective Studies
- Treatment Outcome
- Urethra
- Urinary Bladder, Neurogenic
(complications, drug therapy, physiopathology)
- Urinary Bladder, Underactive
(complications, drug therapy, physiopathology)
- Urinary Retention
(drug therapy, etiology, physiopathology)
- Urodynamics
(physiology)
- Urological Agents
(administration & dosage)
- Video Recording
|